Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$120,000.00
Investigating the Role of RAS in Resistance to Targeted Therapies in BRAF-Mutant Colorectal Cancer
EF 2024-25
Résumé
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Canada. Around 10% of CRC cases are driven by a mutation in the BRAF gene, a key component of the MAPK signaling pathway, which promotes uncontrolled tumor growth by maintaining continuous activation of this pathway. While drugs targeting proteins in this pathway can be effective in other cancers with this mutation, they only work for about 25% of CRC patients, leaving many without successful treatment options.
A major reason these therapies fail is that some tumors develop resistance, often involving acquiring mutations in another gene called RAS. Mutations in RAS cause tumors to bypass the effects of inhibiting the MAPK pathway, leading to cancer regrowth. Our project aims to understand how acquired RAS mutations drive resistance to these treatments and to develop more effective therapies for patients with BRAF-mutant CRC.
We will focus on three main goals:
Identify how resistance develops: We have created CRC cell models that are resistant to approved therapies targeting the MAPK pathway. By comparing these resistant cells with non-resistant ones, we aim to investigate how RAS contributes to treatment resistance in these tumors.
Test the impact of RAS mutations: Using engineered CRC cells with common RAS mutations, we will study how these changes affect the response to MAPK pathway inhibitors and other therapies.
Evaluate new treatment strategies: We will test a new drug combination targeting both BRAF and RAS-driven mechanisms in both cell lines and in animal models of BRAF-mutant CRC.
Our goal is to develop better treatment strategies for patients with BRAF-mutant CRC who currently have limited options. By targeting the resistance mechanisms, we hope to create therapies that are more effective in both newly diagnosed and treatment-resistant cases. Ultimately, our research could lead to new clinical trials that improve outcomes for CRC patients.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518878
Name
Maxwell Jennifer L
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Role of RAS in Resistance to Targeted Therapies in BRAF-Mutant Colorectal Cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Braf + Mek Inhibition; Braf V600 Mutations; Braf:Craf Heterodimerization; Clonogenic Growth Assays; Colorectal Cancer; Egfr Inhibition; Immunoblotting; Ras Mutations; Treatment Resistance; Xenografts
Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in Canada. Around 10% of CRC cases are driven by a mutation in the BRAF gene, a key component of the MAPK signaling pathway, which promotes uncontrolled tumor growth by maintaining continuous activation of this pathway. While drugs targeting proteins in this pathway can be effective in other cancers with this mutation, they only work for about 25% of CRC patients, leaving many without successful treatment options.
A major reason these therapies fail is that some tumors develop resistance, often involving acquiring mutations in another gene called RAS. Mutations in RAS cause tumors to bypass the effects of inhibiting the MAPK pathway, leading to cancer regrowth. Our project aims to understand how acquired RAS mutations drive resistance to these treatments and to develop more effective therapies for patients with BRAF-mutant CRC.
We will focus on three main goals:
Identify how resistance develops: We have created CRC cell models that are resistant to approved therapies targeting the MAPK pathway. By comparing these resistant cells with non-resistant ones, we aim to investigate how RAS contributes to treatment resistance in these tumors.
Test the impact of RAS mutations: Using engineered CRC cells with common RAS mutations, we will study how these changes affect the response to MAPK pathway inhibitors and other therapies.
Evaluate new treatment strategies: We will test a new drug combination targeting both BRAF and RAS-driven mechanisms in both cell lines and in animal models of BRAF-mutant CRC.
Our goal is to develop better treatment strategies for patients with BRAF-mutant CRC who currently have limited options. By targeting the resistance mechanisms, we hope to create therapies that are more effective in both newly diagnosed and treatment-resistant cases. Ultimately, our research could lead to new clinical trials that improve outcomes for CRC patients.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Maxwell, Jennifer L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~